Develop Business Strategies Of Irritable Bowel Syndrome Market - Global Drug Forecast and Analysis to 2026

"The Latest Research Report PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Irritable bowel syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. IBS is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least three months. IBS is classified into three main subtypes, according to the predominant bowel habit: constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed-presentation (IBS-M) IBS.

The IBS treatment landscape remains largely underserved, and ample opportunity exists for pharmaceutical companies to address the numerous unmet needs in this therapy area. Based on insights gathered from primary and secondary research, GlobalData anticipates that two of the new drugs, tenapanor and SYN-010, will have an initial slow uptake, as opposed to Trulance (plecanatide), which has a similar mode of action (MOA) to that of Linzess/Constella (linaclotide). The sales are expected to grow steadily over the forecast period, primarily due to the increased prevalent population and the launch of novel agents to treat IBS-C.

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/1686305

This model covers the market forecast for IBS marketed therapies and late-stage pipeline candidates. The base year of this model is 2016 and the forecast period is 2017-2026.

Scope

- Overview of IBS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline market revenue from 2016-2026 for IBS. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting prescription drug sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global prescription drug market for IBS. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global prescription drug market for IBS.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the prescription drug market for IBS in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Browse Complete Report with TOC @ https://www.marketresearchreports.biz/reports/1686305/pharmapoint-irritable-bowel-syndrome-ibs-market-research-reports/toc

Table of Contents

1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 9

2 Executive Summary 10
2.1 The IBS Market Expected to Experience Solid Growth from 2016-2026 11
2.2 Companies Leverage Partnerships to Successfully Develop and Commercialize IBS Products 12
2.3 The IBS Market is Characterized by Significant Unmet Needs 14
2.4 Products With Improved Efficacy Will Have Significant Opportunities in the IBS Market 14
2.5 The Potential Introduction of Late-Stage Pipeline Products Will Drive Growth in the IBS Market 14
2.6 What Do Physicians Think 15

3 Introduction 18
3.1 Catalyst 18
3.2 Related Reports 19
3.3 Upcoming Related Reports 19

4 Disease Overview 20
4.1 Etiology and Pathophysiology 20
4.1.1 Etiology 20
4.1.2 Pathophysiology 21
4.2 Classification or Staging Systems 26
4.3 Symptoms 27
4.4 Prognosis 27
4.5 Quality of Life 28

5 Epidemiology 29
5.1 Disease Background 29
5.2 Risk Factors and Comorbidities 30
5.3 Global and Historical Trends 31
5.3.1 US 33
5.3.2 5EU 34
5.3.3 Japan 35
5.4 Forecast Methodology 35
5.4.1 Sources 36
5.4.2 Forecast Assumptions and Methods 40
5.5 Epidemiological Forecast for IBS (2016-2026) 46
5.5.1 Total Prevalent Cases of IBS 46
5.5.2 Diagnosed Prevalent Cases of IBS 47
5.5.3 Age-Specific Diagnosed Prevalent Cases of IBS 48
5.5.4 Sex-Specific Diagnosed Prevalent Cases of IBS 49
5.5.5 Diagnosed Prevalent Cases of IBS by Clinical Subtype 50
5.5.6 Diagnosed Prevalent Cases of IBS Clinical Subtype by Comorbidity 51
5.6 Discussion 52
5.6.1 Epidemiological Forecast Insight 52
5.6.2 Limitations of the Analysis 54
5.6.3 Strengths of the Analysis 55

View Sample PDF @ https://www.marketresearchreports.biz/reports/1686305/pharmapoint-irritable-bowel-syndrome-ibs-market-research-reports.pdf

6 Disease Management 56
6.1 Diagnosis Overview 56
6.2 Treatment Overview 58
6.2.1 Treatment Guidelines 58
6.2.2 Clinical Practice 58
6.3 US 62
6.4 5EU 64
6.5 Japan 65

7 Competitive Assessment 68
7.1 Overview 68
7.2 Product Profiles - Major Brands, IBS-C Therapy 70
7.2.1 Linzess (linaclotide) 70
7.2.2 Amitiza (lubiprostone) 74
7.3 Product Profiles - Major Brands, IBS-D Therapy 77
7.3.1 Xifaxan (rifaximin) 77
7.3.2 Viberzi (eluxadoline) 84
7.3.3 Lotronex (alosetron) 89
7.3.4 Irribow (ramosetron) 92
7.4 Product Profiles - Therapeutic Agents for All IBS Clinical Subtypes 95
7.4.1 Antidepressants 95
7.5 Other Minor Therapeutic Classes 97
7.5.1 OTCs and Non-pharmacological Treatment Options for IBS 97
7.5.2 Off-Label Prescription Treatment Alternatives for IBS 99

8 Unmet Needs and Opportunity Analysis 101
8.1 Overview 101
8.2 More Efficacious Prescription Drugs Indicated for IBS 102
8.2.1 Unmet Need 102
8.2.2 Gap Analysis 103
8.2.3 Opportunity 104
8.3 Novel Therapies for IBS-D Patients 104
8.3.1 Unmet Need 104
8.3.2 Gap Analysis 105
8.3.3 Opportunity 105
8.4 Drugs Specifically Approved for IBS-M Patients 105
8.4.1 Unmet Need 105
8.4.2 Gap Analysis 106
8.4.3 Opportunity 106
8.5 Therapies to Address Abdominal Pain and Bloating Associated with IBS 106
8.5.1 Unmet Need 106
8.5.2 Gap Analysis 107
8.5.3 Opportunity 107

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.